The cell cycle inhibitor p21 CDKN1A is a protein playing multiple roles not only in the DNA
damage response, but also in many cellular processes during unperturbed cell growth. The …

Most human cancers harbor mutations in the gene encoding p53. As a result, research on
p53 in the past few decades has focused primarily on its role as a tumor suppressor. One …

The discovery of human-induced pluripotent stem cells (iPSCs) has sparked great interest in
the potential treatment of patients with their own in vitro differentiated cells. Recently …

Completion of early stages of tumorigenesis relies on the dynamic interplay between the
initiating oncogenic event and the cellular context. Here, we review recent findings …

The role of p53 as the “guardian of the genome” in differentiated somatic cells, triggering
various biological processes, is well established. Recent studies in the stem cell field have …

Cell reprogramming technology has allowed the in vitro control of cell fate transition, thus
allowing for the generation of highly desired cell types to recapitulate in vivo developmental …

Induced pluripotent stem cells are powerful tools for disease modeling, drug screening, and
cell transplantation therapies. These cells can be generated directly from somatic cells by …

It is well accepted that expression of mutant p53 involves the gain of oncogenic-specific
activities accentuating the malignant phenotype. Depending on the specific cancer type …

Serine and glycine are amino acids that provide the essential precursors for the synthesis of
proteins, nucleic acids and lipids. Employing 3 subsequent enzymes, phosphoglycerate …

Tumour evolution is driven by both genetic and epigenetic changes. CENP-A, the
centromeric histone H3 variant, is an epigenetic mark that directly perturbs genetic stability …